• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 8

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business...

“Neuropharmacology: Psychedelics on the Brain” – Jim Harris, Rachel Zoeller, DPT, David W. Mcmillan, Ph.D., and Manesh Girn, Ph.D.

mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims...

Kama Flight: The Healing Power of Somatic Movement, Communication, and Trust

PsychedeliCare Launches First European Citizens’ Initiative Demanding Political Action on Psychedelic-Assisted...

Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to...

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic...

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

Natural Medicine Advisory Bulletin 15: A Duplicitous December

Pot for the People: Debunking Cannabis Myths and Empowering Consumers

1...789...286Page 8 of 286

EDITOR PICKS

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic...

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©